| Nivolumab versus everolimus in advanced renal-cell carcinoma RJ Motzer, B Escudier, DF McDermott, S George, HJ Hammers, S Srinivas, ... New England Journal of Medicine 373 (19), 1803-1813, 2015 | 6319 | 2015 |
| Post-acute COVID-19 syndrome A Nalbandian, K Sehgal, A Gupta, MV Madhavan, C McGroder, ... Nature medicine 27 (4), 601-615, 2021 | 5324 | 2021 |
| The immune landscape of cancer V Thorsson, DL Gibbs, SD Brown, D Wolf, DS Bortone, THO Yang, ... Immunity 48 (4), 812-830. e14, 2018 | 5047 | 2018 |
| Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma RJ Motzer, NM Tannir, DF McDermott, O Arén Frontera, B Melichar, ... New England Journal of Medicine 378 (14), 1277-1290, 2018 | 4534 | 2018 |
| Comprehensive molecular characterization of clear cell renal cell carcinoma Cancer Genome Atlas Research Network Analysis working group: Baylor College ... Nature 499 (7456), 43-49, 2013 | 3860* | 2013 |
| Pembrolizumab as second-line therapy for advanced urothelial carcinoma J Bellmunt, R De Wit, DJ Vaughn, Y Fradet, JL Lee, L Fong, NJ Vogelzang, ... New England Journal of Medicine 376 (11), 1015-1026, 2017 | 3477 | 2017 |
| Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma RJ Motzer, K Penkov, J Haanen, B Rini, L Albiges, MT Campbell, ... New England Journal of Medicine 380 (12), 1103-1115, 2019 | 2478 | 2019 |
| Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor–targeted agents: results from a large … DYC Heng, W Xie, MM Regan, MA Warren, AR Golshayan, C Sahi, ... Journal of clinical oncology 27 (34), 5794-5799, 2009 | 2422 | 2009 |
| Pazopanib versus sunitinib in metastatic renal-cell carcinoma RJ Motzer, TE Hutson, D Cella, J Reeves, R Hawkins, J Guo, P Nathan, ... New England Journal of Medicine 369 (8), 722-731, 2013 | 2216 | 2013 |
| Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study NM Kuderer, TK Choueiri, DP Shah, Y Shyr, SM Rubinstein, DR Rivera, ... The Lancet 395 (10241), 1907-1918, 2020 | 1968 | 2020 |
| Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma R Motzer, B Alekseev, SY Rha, C Porta, M Eto, T Powles, V Grünwald, ... New England Journal of Medicine 384 (14), 1289-1300, 2021 | 1530 | 2021 |
| Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma TK Choueiri, T Powles, M Burotto, B Escudier, MT Bourlon, B Zurawski, ... New England Journal of Medicine 384 (9), 829-841, 2021 | 1496 | 2021 |
| Cabozantinib versus everolimus in advanced renal-cell carcinoma TK Choueiri, B Escudier, T Powles, PN Mainwaring, BI Rini, F Donskov, ... New England Journal of Medicine 373 (19), 1814-1823, 2015 | 1345 | 2015 |
| Systemic therapy for metastatic renal-cell carcinoma TK Choueiri, RJ Motzer New England Journal of Medicine 376 (4), 354-366, 2017 | 1237 | 2017 |
| Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma DF McDermott, MA Huseni, MB Atkins, RJ Motzer, BI Rini, B Escudier, ... Nature medicine 24 (6), 749-757, 2018 | 1157 | 2018 |
| External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study DYC Heng, W Xie, MM Regan, LC Harshman, GA Bjarnason, ... The lancet oncology 14 (2), 141-148, 2013 | 1144 | 2013 |
| Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial TK Choueiri, B Escudier, T Powles, NM Tannir, PN Mainwaring, BI Rini, ... The lancet oncology 17 (7), 917-927, 2016 | 1122 | 2016 |
| Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma D Miao, CA Margolis, W Gao, MH Voss, W Li, DJ Martini, C Norton, ... Science 359 (6377), 801-806, 2018 | 1114 | 2018 |
| Marital status and survival in patients with cancer AA Aizer, MH Chen, EP McCarthy, ML Mendu, S Koo, TJ Wilhite, ... Journal of clinical oncology 31 (31), 3869-3876, 2013 | 1109 | 2013 |
| Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets PK Brastianos, SL Carter, S Santagata, DP Cahill, A Taylor-Weiner, ... Cancer discovery 5 (11), 1164-1177, 2015 | 1097 | 2015 |
Sumanta PalCity of HopeZweryfikowany adres z coh.org